Product Approval / Regulatory Milestone
Alembic Pharma Secures USFDA Approval for Fingolimod Capsules (0.5 mg)
NSE
aplltd
BSE
533573
Alembic Pharmaceuticals has received USFDA final approval for Fingolimod Capsules (0.5 mg), a generic equivalent of Gilenya, targeting a ~$145 million US market
PRICE-SENSITIVE TRIGGER
Event: USFDA ANDA Final Approval
Type: Product Approval / Regulatory Milestone
Impact: Neutral
Immediate Effect: Expands Alembic’s US generics portfolio and strengthens revenue visibility in a high-value therapeutic segment
Key Metrics:
- Estimated Market Size: US$ 145 million (IQVIA, Dec 2025 MAT)
- Total ANDA Approvals: 237 (219 final + 18 tentative)
Highlight:
- US$ 145 million market opportunity in the US generics space
What Happened ?
Alembic Pharmaceuticals Limited has received final approval from the USFDA for its ANDA for Fingolimod Capsules 0.5 mg, a generic equivalent of Novartis’ Gilenya, used in treating multiple sclerosis
key highlights
Product & Market Expansion:
- ANDA approved for Fingolimod Capsules (0.5 mg)
- Generic equivalent of Gilenya by Novartis
- Used for treatment of relapsing multiple sclerosis (MS)
- Targets US market with ~$145 million size
- Applicable for patients aged 10 years and above
- Strengthens Alembic’s US generics pipeline
- Total cumulative USFDA approvals now at 237
Note:
- Approval enhances Alembic’s presence in complex generics and CNS therapeutic segment
Risk Analysis
Key Risks
- High competition in generic drug space
- Pricing pressure in US pharma market
- Regulatory compliance and supply execution risks
- Dependence on successful commercialization
Worst Case Scenario
- Delayed commercialization or pricing erosion limits expected revenue contribution
Risk Level: Medium
Company Commentary
- Approval reflects strong regulatory and R&D capabilities
- Continues expansion in complex generics portfolio
- Focus on global markets, especially US
Official Exchange Filing: Alembic Pharmaceuticals Limited